

REMARKS

Method-of-use Claims 37-47 are the only claims now pending in this application. Method-of-use Claims 37-47 define a method for treating renal failure by use of a renin-inhibiting compound defined in the chemical recitations therein.

* * *

In response to Examiner's request, marked-up versions of the earlier-presented new Abstract and new Page 1 showing a revised "Title" and description of "Related Applications" are attached hereto.

* * *

Method-of-use Claims 37-47 stand rejected under the judicially-created doctrine of obviousness-type double patenting as being unpatentable over Claims 1-11 of U.S. Patent No. 6,342,624.


U.S. Patent 6,342,624 and the subject Application are co-owned by Applicants' Assignee.

This rejection is rendered moot by introduction herewith of a Terminal Disclaimer, in compliance with 37 C.F.R. §1.321(b), for the claims of the subject Application over the term of cited U.S. Patent 6,342,624.

* * *

In view of foregoing Remarks, Claims 37-47 should be in condition for allowance.

Respectfully submitted,


J. Timothy Keane
Attorney for Applicants
Registration No. 27,808
314-274-9090

Pharmacia Corporation
Global Patent Department
P.O. Box 1027
Chesterfield, MO 63006

Attachments

Marked-Up Versions of New Abstract and Amended Page 1
Clean Copies of New Abstract and Amended Page 1
Terminal Disclaimer